CASE REPORT article
Front. Genet.
Sec. Pharmacogenetics and Pharmacogenomics
Volume 16 - 2025 | doi: 10.3389/fgene.2025.1569912
Successful Late-Line Pralsetinib Treatment in an ALK-Rearranged Lung Adenocarcinoma Patient with KIF5B-RET Fusion Resistant to Alectinib: A Case Study
Provisionally accepted
- Shenzhen Hospital, Peking University, Shenzhen, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Anaplastic lymphoma kinase (ALK) fusion, an oncogenic driver alteration, accounts for 5%-6% of non-small cell lung cancer (NSCLC) patients. ALK tyrosine kinase inhibitors (TKIs) provide significant clinical benefit in advanced ALKrearranged NSCLC. effectively treat advanced ALK-rearranged NSCLC. However, acquired resistance to ALK TKIs inevitably arisesdevelops in patients,. and tThe underlying mechanisms remain incompletely elucidatedresistance mechanism remains not fully understood. This report describespresents a case of a stage IV lung adenocarcinoma (LUAD) patient with ALK-rearranged who developed KIF5B-RET fusion-mediated resistance followingto second-line alectinib therapytreatment. The patient achieved awas evaluated as partial response (PR) to third-line pralsetinib , sustained for in the third-line treatment, and it lasted for 4 months. This case highlightsreport revealed KIF5B-RET fusion as a potential resistance mechanism after second-linepost alectinib treatment, and suggested that the =RET inhibitor pralsetinib,
Keywords: Lung Adenocarcinoma, KIF5B-RET, Alectinib, Pralsetinib, case report
Received: 02 Feb 2025; Accepted: 02 Jun 2025.
Copyright: © 2025 Jin, Wang, Yang, Wang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Fen Wang, Shenzhen Hospital, Peking University, Shenzhen, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.